ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

EPCCS 2019 Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.

The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.

ESC HF 2019 In this debate, Douglas Packer and John Cleland took opposite sides of the statement that all patients with atrial fibrillation and heart failure should receive ablation. With poll.

ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.

EPCCS 2019 Read an impression of the presentation of prof. Van der Meer, on the latest recommendations on management of HF, including important aspects to consider in patients with comorbidities.

EPCCS 2019 Slides prepared and presented by prof. Peter van der Meer (Groningen, The Netherlands), here offered as an educational service.

Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.

HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF.